Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be eligible for and enrolled on classification study COG-AALL03B1~* Newly diagnosed B-precursor acute lymphoblastic leukemia~  * WBC \> 50,000/mm\^3 for patients age 1 to 9~ * Any WBC for patients age 10 to 30 OR patients who have received prior steroid therapy OR patients with testicular disease~* Whit blood cell (WBC) criteria:~  * Age 1 - 9 years: WBC \>= 50,000/uL~ * Age 10 - 30 years: any WBC~ * Prior steroid therapy: any WBC~ * Testicular disease: any WBC~* Patients shall have had no other prior cytotoxic chemotherapy with the exception of steroids and intrathecal cytarabine~* Patients receiving prior steroid therapy (as described in AALL03B1) are eligible for study; the dose and duration of previous steroid therapy should be carefully documented~* All patients and/or their parents or legal guardians must sign a written informed consent~* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met~Exclusion Criteria:~* Patients with Down syndrome are ineligible to enroll onto this study

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients in arm I receive intrathecal cytarabine in week 1; infusions of vincristine and daunorubicin once a week in weeks 1-4; dexamethasone by mouth or infusion twice a day in weeks 1 and 2; intrathecal methotrexate in weeks 2 and 5 or 2-5; and an injection of pegaspargase in week 1.
- Arm II (Type: ACTIVE_COMPARATOR): Patients in arm II will receive intrathecal cytarabine in week 1; infusions of vincristine and daunorubicin once a week in weeks 1-4; dexamethasone by mouth or infusion twice a day in weeks 1 and 2; intrathecal methotrexate in weeks 2 and 5 or 2-5; and an injection of pegaspargase in week 1.
- Arm III (Type: EXPERIMENTAL): Patients in arm III will receive cytarabine, vincristine, daunorubicin, and pegaspargase as in groups one and two. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and intrathecal methotrexate in weeks 2 and 5.~Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
- Arm IV (Type: EXPERIMENTAL): Patients in arm IV will receive cytarabine, vincristine, daunorubicin, and pegaspargase as in groups one and two. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and intrathecal methotrexate in weeks 2 and 5.~Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy by infusion, injection, intrathecally, and by mouth for up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).